EG 427 Secures €27 Million in Series B Funding
Deal News | Feb 20, 2025 | MTS Health Partners LP
EG 427, a biotechnology firm specializing in genetic medicines for chronic diseases in neurology, has successfully closed a €27 million Series B funding round. This round was co-led by Andera Partners and Bpifrance, and included contributions from SCI Ventures and existing investors. The capital raised will predominantly fund the phase 1b/2a clinical development of their leading product EG110A, aimed at treating neurogenic detrusor overactivity in spinal cord injury patients. Their proprietary HERMES technology platform underpins EG 427’s innovative approach to neuro-therapeutics, with potential applicability across diverse neuro-urology pathologies. This funding marks a pivotal stage for EG 427 as it aims to disrupt current treatment paradigms and address significant unmet medical needs in neuro-urology, consequently offering cost-effective solutions to healthcare systems. Additionally, MTS Health Partners served as the exclusive financial advisor for this financing round.
Sectors
- Biotechnology
- Healthcare
- Private Equity and Venture Capital
Geography
- France – EG 427 is based in Paris, and both Andera Partners and Bpifrance, major investors in the funding round, are also France-based.
- United States – The phase 1b/2a study of EG110A is scheduled to take place in the United States, signifying the geographical focus of its clinical development activities.
Industry
- Biotechnology – EG 427 operates in the biotechnology sector, focusing on genetic medicines to treat neurological conditions, a core application in the biotech field.
- Healthcare – The article addresses advances in healthcare, particularly through innovative treatments for neuro-urology pathologies, impacting patient care and healthcare systems.
- Private Equity and Venture Capital – The funding round involves major private equity and venture capital firms such as Andera Partners and Bpifrance, highlighting investment activities in life sciences.
Financials
- €27 million – Total amount raised by EG 427 in the Series B funding round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| EG 427 | Target Company | Company | A biotechnology company specializing in developing genetic medicines for chronic diseases in neurology. |
| Andera Partners | Co-Investor | Company | A private equity firm co-leading the Series B funding, focusing on supporting growth in life sciences. |
| Bpifrance | Co-Investor | Company | The French national investment bank co-leading the Series B funding, dedicated to supporting business development. |
| SCI Ventures | Investor | Company | A specialist fund backed by major spinal cord injury foundations participating in the funding round. |
| MTS Health Partners | Financial Advisor | Company | Served as the exclusive financial advisor to EG 427 in this financing round. |
| Philippe Chambon | CEO of EG 427 | Person | Chief Executive Officer at EG 427, providing insight into the company’s strategic focus and funding allocation. |
| Benoît Barteau | Investment Director at Bpifrance | Person | Investment Director associated with the InnoBio funds, highlighting the strategic vision behind the investment. |
| Raphaël Wisniewski | Partner at Andera Partners | Person | A partner at Andera Partners, providing comments on the strategic importance of the funding for EG 427. |